PMID- 11585001
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20190915
IS  - 1465-6566 (Print)
IS  - 1465-6566 (Linking)
VI  - 2
IP  - 8
DP  - 2001 Aug
TI  - Dalteparin sodium.
PG  - 1325-37
AB  - Dalteparin sodium (Fragmin, Pharmacia Corporation) is a low molecular weight 
      heparin (LMWH) with a mean molecular weight of approximately 5000 Da. As with the 
      other LMWHs, dalteparin sodium has certain advantages over unfractionated heparin 
      (UFH), most important of which are improved bio-availability by sc. injection, a 
      prolonged antithrombotic activity which is highly correlated with body weight 
      permitting the o.d. administration of the drug. Dalteparin sodium has been 
      subjected to a large number of well-designed randomised clinical trials for the 
      prevention and treatment of thrombotic disorders. Based on data from the 
      randomised clinical trials, dalteparin sodium has been approved internationally 
      for a wide spectrum of clinical indications (e.g., prevention of thromboembolic 
      events after surgery). Dalteparin sodium has also been studied in randomised 
      controlled trials in the maintenance of graft patentcy following peripheral 
      vascular surgery, in place of warfarin for the long-term treatment of patients 
      presenting with deep vein thrombosis (DVT), in the prevention of upper extremity 
      thrombosis in patients with indwelling portacath devices and in pregnant patients 
      with a history of previous venous thromboembolism with or without thrombophilia. 
      Dalteparin sodium has been compared with heparin for the prevention of thrombotic 
      complications during haemodyalisis and haemofiltration. These studies have shown 
      promising results but further work is required before dalteparin sodium can be 
      recommended for these indications.
FAU - Pineo, G F
AU  - Pineo GF
AD  - University of Calgary, Thrombosis Research Unit, Foothills Hospital, AB, Canada. 
      jeanne.sheldon@crha-health.ab.ca
FAU - Hull, R D
AU  - Hull RD
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Anticoagulants)
RN  - S79O08V79F (Dalteparin)
SB  - IM
MH  - Animals
MH  - Anticoagulants/chemistry/pharmacokinetics/*therapeutic use
MH  - Clinical Trials as Topic/methods/statistics & numerical data
MH  - Dalteparin/chemistry/pharmacokinetics/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/drug therapy/metabolism
MH  - Venous Thrombosis/*drug therapy/metabolism
RF  - 97
EDAT- 2001/10/05 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/10/05 10:00
PHST- 2001/10/05 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/10/05 10:00 [entrez]
AID - 10.1517/14656566.2.8.1325 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2001 Aug;2(8):1325-37. doi: 10.1517/14656566.2.8.1325.